<SEC-DOCUMENT>0001144204-15-016848.txt : 20150318
<SEC-HEADER>0001144204-15-016848.hdr.sgml : 20150318
<ACCEPTANCE-DATETIME>20150318060135
ACCESSION NUMBER:		0001144204-15-016848
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150317
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150318
DATE AS OF CHANGE:		20150318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cellectar Biosciences, Inc.
		CENTRAL INDEX KEY:			0001279704
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043321804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36598
		FILM NUMBER:		15708679

	BUSINESS ADDRESS:	
		STREET 1:		3301 AGRICULTURE DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53716
		BUSINESS PHONE:		617-244-1616

	MAIL ADDRESS:	
		STREET 1:		3301 AGRICULTURE DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53716

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVELOS THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050617

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COMMON HORIZONS INC
		DATE OF NAME CHANGE:	20040211
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v404822_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B><BR>
<B>SECURITIES AND EXCHANGE COMMISSION</B><BR>
Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">___________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">___________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report: March 17, 2015<BR>
(<I>Date of earliest event reported</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CELLECTAR BIOSCIENCES, INC.</B><BR>
(<I>Exact name of registrant as specified in its charter</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; padding-right: 0.2in; padding-left: 0.2in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Delaware</B></P></TD>
    <TD STYLE="width: 33%; padding-right: 0.2in; padding-left: 0.2in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>333-119366</B></P></TD>
    <TD STYLE="width: 33%; padding-right: 0.2in; padding-left: 0.2in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>04-3321804</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(State or other jurisdiction</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>of incorporation)</I></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Commission</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>File Number)</I></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(IRS Employer</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Identification Number)</I></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>3301 Agriculture Drive </B><BR>
<B>Madison, WI 53716</B><BR>
(<I>Address of principal executive offices</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(608) 441-8120</B><BR>
(<I>Registrant's telephone number, including area code</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#9;Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#9;Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#9;Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#9;Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 7.01&#9;REGULATION FD DISCLOSURE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 17, 2015, we issued a press release announcing that
management will host a conference call and live webcast to discuss fourth quarter and full year 2014 financial results and provide
an update on each of its development programs on Tuesday, March 24th at 5:00 PM ET. A copy of the press release is furnished as
Exhibit 99.1 and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 9.01 &#9;FINANCIAL STATEMENTS AND EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 17%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Number</FONT></TD>
    <TD STYLE="width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 67%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Press release dated March 17, 2015, entitled &ldquo;Cellectar Biosciences to Host Conference Call on March 24th to Discuss Fourth Quarter and Full Year 2014 Results and Provide Update on Development Progress&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SIGNATURE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Dated:&nbsp;&nbsp;March 18, 2015</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><B>CELLECTAR BIOSCIENCES, INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 1%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 49%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding: 0; text-indent: 0">By:&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><I>/s/&nbsp;&nbsp;Chad J. Kolean</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Name:&nbsp;&nbsp;Chad J. Kolean </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Title:&nbsp;&nbsp;Vice President and Chief Financial Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Number</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Title</FONT></TD>
    </TR>
<TR>
    <TD STYLE="vertical-align: top; width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 67%"><FONT STYLE="font-size: 10pt">Press release dated March 17, 2015, entitled &ldquo;Cellectar Biosciences to Host Conference Call on March 24th to Discuss Fourth Quarter and Full Year 2014 Results and Provide Update on Development Progress&rdquo;</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v404822_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Cellectar Biosciences
to Host Conference Call on March 24th to Discuss <BR>
Fourth Quarter and Full Year 2014 Results and Provide Update on <BR>
Development Progress</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MADISON, Wis., March 17, 2015,</B> &ndash;
Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection
and treatment of cancer,<B> </B>announced that management will host a conference call and live webcast to discuss fourth quarter
and full year 2014 financial results and provide an update on each of its development programs on Tuesday, March 24th at 5:00 PM
ET.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Event Details:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interested investors may participate in
the conference call by dialing 888-646-8293 (domestic) or 973-453-3065 (international). A replay will be available for one week
following the call by dialing 855-859-2056 for domestic participants or 404-537-3406 for international participants and entering
conference ID 8981874 when prompted. Participants may also access both the live and archived webcast of the conference call on
the investor relations section of Cellectar&rsquo;s web site, www.cellectar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>To Ask Questions:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following prepared remarks and time permitting,
management will provide an opportunity for participants dialed into the live teleconference to ask questions. Investors may also
e-mail their questions to ir@cellectar.com. E-mail questions will be accepted until 12:00 noon ET on Tuesday, March 24th, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Cellectar Biosciences, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cellectar Biosciences is developing agents
to detect, treat and monitor a broad spectrum of cancers. Using a novel phospholipid ether analog (PLE) platform technology as
a targeted delivery and retention vehicle, Cellectar&rsquo;s compounds are designed to be selectively taken up and retained in
cancer cells including cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery
platform, Cellectar has developed a portfolio of product candidates engineered to leverage the unique characteristics of cancer
cells to &ldquo;find, treat and follow&rdquo; malignancies in a highly selective way. I-124-CLR1404 is a small-molecule, broad-spectrum,
cancer-targeted PET imaging agent currently being evaluated in a Phase II glioblastoma imaging trial. Additionally, multiple investigator-sponsored
Phase I/II clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted
molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells including cancer stem cells.
A Phase Ib dose-escalation trial of I-131-CLR1404 in patients with advanced solid tumors was completed in the first quarter of
2014 and results presented at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting. CLR1502 is a preclinical,
cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.
For additional information please visit <FONT STYLE="color: Blue"><U>www.cellectar.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INVESTOR CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kate McNeil, Vice President of IR, PR &amp; Corporate Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cellectar Biosciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: (347) 204-4226</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: <FONT STYLE="color: Blue"><U>kmcneil@cellectar.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This news release contains forward-looking
statements.&nbsp; You can identify these statements by our use of words such as &quot;may,&quot; &quot;expect,&quot; &quot;believe,&quot;
&quot;anticipate,&quot; &quot;intend,&quot; &quot;could,&quot; &quot;estimate,&quot; &quot;continue,&quot; &quot;plans,&quot; or
their negatives or cognates.&nbsp;&nbsp; These statements are only estimates and predictions and are subject to known and unknown
risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.&nbsp;
These statements are based on our current beliefs and expectations as to such future outcomes.&nbsp; Drug discovery and development
involve a high degree of risk.&nbsp; Factors that might cause such a material difference include, among others, uncertainties related
to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies,
the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA
review process and other government regulation, our&nbsp;pharmaceutical collaborators' ability to successfully develop and commercialize
drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description
of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange
Commission including our Form 10-K for the year ended December 31, 2013. These forward-looking statements are made only as of the
date hereof, and we disclaim any obligation to update any such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0; text-align: right"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!*`1<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBL_6M:
ML-`TV2_U&<10IP.[.>RJ.Y--)MV0&A6=>Z]I&G3)#=ZE:PS.P58WE&XDG`&.
MM>'^)_B9K.O2/#9R/IUB>!'$V)''^TP_D,?C7*Z5_P`ANP8\DW462>I^<5Z%
M/+W:\W8ER/JNO//BWKU]HVAV,>G7<MK/<3G+Q-AMJJ3C/U(KT.O/_B%X<?Q'
MJVDQ"X$:PDDH1G.YAG]%KBI5*=.HI57H.3T.VTTSG2K,W+;YS`GF-C&6VC)_
M.IIYX;6WDN)Y%BAC4L[N<!0.I)I)YX;2VDGGD6*&)2SNQP%`[UXWK6MZM\3]
M<&B:&K1:3&VZ21@0&`/WW]O[J]_Y72I.JV]DMV#=CO/#'CVR\5:U?6%E:3K'
M;IO2X;[LBYQT_A]@>HKK:R/#GARP\,:4EC8I_M2RM]Z5O[Q_P[5KU%5P<O<6
M@(****S&%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`,FFCMX))YG"11J7=FZ*`,DFOF[QEXKN/%FM/<%F6RB)6UA/1
M5_O$?WCU/Y=J]5^+FL-I_A-;*)MLFH2^4<?\\QRW]!^->'V=I-?WUO9VZ[I[
MB18HQ[DX%>K@*24759$GT-CPKX1U'Q9?&&T`BMXR//N7'RI[#U;VKVS0OAUX
M=T)8W6S6[NDP?M%R-[9]0.@_`5L:!HEKX>T6WTVT4;(E^9L<NW=C[DU>N+F*
MUB,LSA5'KWKEQ.,E-NSM'^MQI)$M9-W8.VK1WSRHL$0!.3R,9IO_``D=IOQY
M<VW^]@?XT:A#-J\<!M)T-L3\_/?_`#VKR:E2G5C[GO-:V7];`VFM#+U59?%*
MR:=#E;4CEC_,_P!!6OX?\/6'AK3%LK"/:N=TDA^](WJ3_G%$]M<V%E'%IB`M
MN^=CC)]^:P==T#Q'K>F/;1:D;21F!W>:5X_X#54)U(R]E._O/5]%_P`,):,Z
MV>\M;4J+BYAB+'`\QPN3^-35Y3:_!6&1A)JFMSSMGYA%&`3_`,"8DUZI&@BC
M6-<[5`49.>!7=5C3C;DE?Y%(=16-JGBC3=+NULF::YOF&X6EI$99<>I`Z#ZX
MJH?&$<(WWFAZU:PCK*]IN51ZG821^52J<VKV&=)15>QO[34K..[LKB.XMY!E
M9(VR#5BH:MHP"BBB@`HHHH`****`"BBB@`HHHH`**1F5!EF"CU)Q0"&`*D$'
MN*`%HHHH`****`"BBB@`HHHH`****`/&OC7,QU72(<_(L$C@>Y8#^E<[\,+=
M+CX@:?O`(C620#W"''\ZZKXV69WZ/?`?+^\A8^AX8?R-<1X$U)-)\;:7<RL%
MB:0PN3T`<%<_F17M4=<):/9_J0]SZ4KE?$$S2:B8B?DC48'N>2:ZJL'7=-DE
M<74"ESC#J.OUKYK&QE*E[HY['/5K^'IV2_:'/R2*21[CO63@[MN#GTQS71:%
MILD!:ZG4JS#:BGJ!ZFO+PD9.LG'H9QW-RN8U;Q_X=T/4Y=/O[N2.YBQO40NP
M&0".0,=#73U\R^,=235_&&J7L;;HFG*1L.ZJ`H/Z5]5A*"K2:ELC5NQ[]H'B
M[1O$TD\>EW#RM``T@:)DP#G'4>QJ[K=^=+T*_OU&YK:W>4#U(4D5YQ\$[-EM
M-7O2#M>2.%3Z[02?_0A7I]Y:Q7UC/:3#,4\;1N/8C!_G6=:$*=5Q6R!:HR/"
M.DQ:;H,$I_>7MXBW%W<-RTLC#))/H,X`["MZN-TC7QX:MHM%\2L;9[8"*"^=
M3Y-S&.%.[HK8QD&M>X\8^&[:+S)-;L2.PCF#L?H%R32J0FY-VO<#1M-.L[![
MA[2VCA-P_F2[!C>V,9(]:XSQ$FC3>/DCUZZ6&T&F!H_,N6A4OYI[@C)QFNJT
M759=8MI+EM/N+.'?B#[1\KRI_?V]5^AYKFM9O](T_P"(HDUF6WC@;20J&=00
M6\T]..N,U5)24W?>S]>@,+71O`5]<I;6EY!/.^=L<>IR,S8&>`']*Z[3M.MM
M*LDL[-&2!"2JL[.>3D\L2:YZ+Q7X)@D$D6H:9&XZ,B`$?CBM_3=5L=8M?M6G
MW4=S!N*;T/&1U%*KSVUO;S!&-X2=FN_$>YF;;JT@&3G`V)P*Z6N$T3Q+HVC:
MGXBM]1U&"VF;59'"2$@E=J#/Z&MR+QOX9GFCABUFU:21@B*&.22<`45*<W*Z
M3_I("#Q4[+JGAD*S*&U,`@'&1Y;\&NFKDO&UW!8W7ARZNI5B@BU(,\C=%'EO
MR:M_\)YX6_Z#=I_WT?\`"DX2E"/*K[_F!T5>6:!;^#[BPFDUO4(4OS=SAUEU
M!XV`$K;?EWC'&*]'TW5;'6+4W6GW4=S`&*;T/&1U%<'X7USPK9:3)!JES8)=
MK=W!99D!8`RL1GCTQ5TE)1DM;Z;;]09LZ;X:\':B3-IKBZ\EQEH;^1PK=1G#
MUM>(]7.A>'[O45C$LD2@1QD_>=B%4?F16;!XR\'6H(M]4L(@QR1&-N?R%:/B
M/2CKWAVZL89`DLJAH9#T#J0RD^V0*EWYU[2]O,#,L_!=G<1+<^(2VK:BXW2O
M.Q,:$]51/NJH^F:F'@^SLKB.YT.>72I58%UA):*5<\JT9..G<8(J.Q\:Z>J+
M;ZXPTG4D&)8;KY%)[E'/RLI[$&I&\::9<745II'F:M<2.`5M!E(USRS.?E``
M]\TW[:_]6_R#0T=6T+3]<6);^)Y!$24V3.F,]?ND9Z5Q]]X3T>'QII&GQPSB
MUN+:X>5/M4OS,NS:<[L\9->A5R^I_P#)1=`_Z]+K_P!ITJ4Y*Z3Z,&:&E^&-
M)T:Z-S8P2)*4*$M/(XP<'HS$=JB\5ZM-IFE+#8X;4[Z06UFO^VW\7T498_2M
MVN"AM]5\5>(9=?TZ_@M+2S+VEBTUOYHD'220#(QDC:#Z"E3]Z7--[=_P`L:)
M;R>#]?BT6:YEGL-1CWV\TSEBMPH_>+D_WA\P^A%=K7%:QX8\3ZK8^5-K]F[Q
M.L\)6QV,LB\J0V\XYX^A-=!X<U@:YHL-VR>5.,QW$)ZQ2KPRG\?TQ3JKF7/>
M[Z@CE/#/AG2=9L[V[U".:6<ZA<IN^U2+P)&`&`P%:5]X,\.6MC-<+)<6)C0N
M+E+Z4&/`Z\MBLWPMX5T/5[&^N[_3XYYSJ-TI=F8$@2MCH:3Q#X+TS27MM;TW
M28[B&T.;NP8%Q+'W903]]>H]>E;.5ZG+S-`=/X1OKO4O"6F7E]DW,L`9V(P6
M]&Q[C!_&BM*QNK:^L8+JSD62VE0-&R="IZ45R3=Y-VL,P_'>@-XC\)W5G$NZ
MYCQ-;^[KV_$9'XU\VD'D$$$<$'@@U];5X]\3/`$J7$VOZ1"7C?+W=N@R5/>1
M1W![C\?6N_`8A1?LY==B9+J=/\.O&\7B'3H]/O90NK6Z88,?]>H_C'J?4?C7
M=5\EPS20RI-!(T<B'<DB-@J?4$5Z)HGQ@U>PC6'5+:/4$48\P-Y<GX\8/Y"J
MQ&!=^:G]PE+N>W[5SG`SZXI:\P_X77IGEY&D7N_^[O3'YYKF]<^+VLZC&T.F
MP1Z=&W'F!O,EQ['&!^5<T<%6;M:Q7,CL_B3XWBT33I-)L)@VJ7";6*G_`%"'
MJQ]&(Z#\:\*1&9E2-2S,0JJHR23P`*621Y)'EE=G=SN9W.2Q]23UKUKX9^`)
M8IHO$&L0E&7YK.W<<@_\]&';V'X^E>DE#"4M=_S9&[.\\&:#_P`(YX6L]/<#
MSPOF3D=Y&Y/Y=/PK>HJIJA(TB](."('Y'^Z:\5MSE=]30LO&DJ%)$5U/56&0
M:KPZ986\GF06-M$_]Y(E4_F!7&:=I#2Z5:2?\(PLQ>!&\TZB5+Y4<X[9ZU:>
M=Y/A[%NF>26.:.-V8\AEF`*Y[XZ9[XK7V=M$^MOZU%<[.FE$<Y*JWN1FL#6\
M7>O:=IMU*\5A-'([*KE//D&,(2.V"3COBJVK:?9Z#]DNM*7[-=O<QQ+#&QVW
M`9@&4KT/&3GMBH4+VUU87.G\J(=8T_(4Y551A0`/85S.L:5<WFM/.L5GJ,2Q
M*HM+B9D\D\_,``0<^X[4[0Y$LKZ[TX::UG=>2)Q$MR98F7)'R_W3GM@4<GNW
M3"YT1CC)R43)]0*/*C!R(T_[Y%<OH6DZ?K>E1ZAJ*_;;V;)F:5B?*;/*`9^7
M'3%7;R&WM?"6J16ET\\<<$P!:;S#&=I^7/7CT/(H<$GRW`W657&&4$>XIODQ
M?\\T_P"^17*:[&\^BZ!$L0G,DT0,32%`_P"[;@L.15W1]"AAN?M%QI$-I+$0
M8FCNGESUSG(%/D2C=L+G0*JJ,*`!Z`4WRH_^>:?]\BN5GMKV7Q9J=UI\Q%U;
M0P%(G;]W*I#;D8=LX&#V-3V.IQZGXKMI8MZ$6,JRPOPT;B1,JP]11[-VNGT"
MYT9BB`YC3_OD4^N6L;&UUW4=3?51]HFM[EHDMG8[8HQC:0O^T.<UKZ=8V6GR
M7,%E.V."UL9MXB^@/*Y_*IE%+2^H%^2*.9=LL:.OHR@BECC2)=L:*B^BC`K@
MM`T9KS3;.:71;>>.3[UPUZX<C<<G;CK[9KH-:TEGTVSLK%X8XXY1_HTTK*LZ
M@'Y"PY]^_2JE!*7+<+F^"#TI,#(.!D=ZY"")-&U.SEN=#CLQ-,(%EM+LLI9N
M`&3`R/SQ785,X\HPI``H````["EHJ`"D"@9P`,\G%+10`@`7H`/I2T44`(%"
MC"@`>@HI:*`"BBB@#@O%'PLTK6Y'N]/?^SKQN6V+F)SZE>Q]QC\:\VU+X8^*
MM/=MEBMY&#P]M(#G\#@_I7T-1772QM6FK;KS$XH^9/\`A#O$V[;_`&!J.?\`
MK@?YUK:;\+_%.H.OF6:649ZO<R`8_P"`C)KZ%HK5YC4:T2%RHX;PO\+])T&1
M+N[;^T+Y>5>1<1QG_97U]SG\*[FBBN*I4E4=Y.Y5K!39(TEB>.10R."K`]P>
MM.HJ`,4>$]"``&FQ`#MD_P"-7SIED;!;'[+&+5<%8@N%&#D<?49JW15.<GNP
M*]Y8VNH6Y@NX$FB)SM<9Y]1Z&JUEH.F:?/Y]M:*LP&!(S%V`]BQ./PK1HI*3
M2M<#/O=#TW4)A/<VB-,!CS5)5\>FX$&I+#2K'3`_V.V2(R<NW)9OJ3R:N44^
M:5K7`R[KPYI-Y</<362^:_WV1F3?]=I&?QJVFG6<5@UC';1I:LI0Q*N%(/6K
M-%'-)Z7`IW>E6-]:Q6US;))#$040YPN!@8_"JT'AK1[:>.>&QC26-@R,">#^
M=:M%"G)*R8$*6L$=S+<I&HFE"K(XZL%SC\LFF+I]HFH/?K;QB[=/+:4#YBOH
M?RJS12NP,^^T33=1F$UU:J\H&!(I*MCTR"#BIK'3;+38FBL[:.%6.6VCECZD
M]3^-6J*.9VM<#&_X1/0NVFQ#Z$_XU:?1-,EL([&2RB>VC.41AG:?4'J#5^BF
MYR?4+&9:^']*L[A;B&T7SD^X[NSE?IN)Q^%:=%%)MO<`HHHI`%%%%`!1110`
&4444`?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
